 Piperidines
"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 2 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 4 | 0 | 4 | | 2006 | 3 | 0 | 3 | | 2007 | 3 | 0 | 3 | | 2008 | 3 | 2 | 5 | | 2009 | 2 | 4 | 6 | | 2010 | 4 | 2 | 6 | | 2011 | 0 | 1 | 1 | | 2012 | 2 | 3 | 5 | | 2013 | 2 | 5 | 7 | | 2014 | 1 | 2 | 3 | | 2015 | 5 | 6 | 11 | | 2016 | 3 | 1 | 4 | | 2017 | 6 | 0 | 6 | | 2018 | 5 | 5 | 10 | | 2019 | 2 | 11 | 13 | | 2020 | 1 | 2 | 3 | | 2021 | 5 | 9 | 14 | | 2022 | 1 | 5 | 6 | | 2024 | 5 | 3 | 8 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
DuBois SG, Ogawa C, Moreno L, Moss? YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Rachubinski AL, Wallace E, Gurnee E, Enriquez-Estrada BA, Worek KR, Smith KP, Araya P, Waugh KA, Granrath RE, Britton E, Lyford HR, Donovan MG, Eduthan NP, Hill AA, Martin B, Sullivan KD, Patel L, Fidler DJ, Galbraith MD, Dunnick CA, Norris DA, Espinosa JM. JAK inhibition decreases the autoimmune burden in Down syndrome. Elife. 2024 Dec 31; 13.
-
Arciniegas DB, Almeida EJ, Sander AM, Bogaards JA, Giacino JT, Hammond FM, Harrison-Felix CL, Hart T, Ketchum JM, Mellick DC, Sherer M, Whyte J, Zafonte RD. Multicenter Evaluation of Memory Remediation in Traumatic Brain Injury With Donepezil: A Randomized Controlled Trial. J Neuropsychiatry Clin Neurosci. 2025; 37(2):102-114.
-
Aldy K, Krotulski A, Brent J, Campleman S, Culbreth R, Logan B, Wax P, Amaducci A, Judge B, Levine M, Schwarz E, Calello DP, Meaden CW, Shulman J, Hughes A, Hendrickson R, Carpenter J, Buchanan J, Manini AF. Emergency Department Patients with Para-Fluorofentanyl Overdose. J Emerg Med. 2025 May; 72:56-69.
-
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV, Singh S. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology. 2024 Dec; 167(7):1460-1482.
-
Rachubinski AL, Patel LR, Sannar EM, Kammeyer RM, Sanders J, Enriquez-Estrada BA, Worek KR, Fidler DJ, Santoro JD, Espinosa JM. JAK inhibition in Down Syndrome Regression Disorder. J Neuroimmunol. 2024 10 15; 395:578442.
-
Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024 Oct 20; 42(30):3606-3617.
-
Yamazaki S, Shimizu M, Yakabe A, Inage E, Jimbo K, Suzuki M, Miyaoka F, Kaneko S, Irabu H, Shimbo A, Ohtomo Y, Mori M, Morio T, Shimizu T. Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature. Immunol Med. 2024 Jun; 47(2):110-117.
-
Gibbons JB, Bennett CL, Carson KR, Anderson GF. Adjusting starting points for initial price offers: the example of ibrutinib. Am J Manag Care. 2024 04; 30(4):193-196.
-
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|